5 microbiome r&d business collaborationforum … · science manager, yakult nederland,...

2 1 - 2 2 M A R C H 2 0 1 8ROTTERDAM, THE NETHERLANDS

5TH MICROBIOME R&D & BUSINESS COLLABORATION FORUM

2ND PROBIOTICS CONGRESS: EUROPE

www.global-engage .com

#MicrobiomeProbioticsForum

WARM WELCOME

Global Engage is pleased to announce, as part of their worldwide microbiome series, the 5th European Microbiome R&D and Business Collaboration Forum and co-located 2nd Probiotics Congress which will be held on March 21-22, 2018 at the World Trade Center in Rotterdam, the Netherlands. The congress which attracted over 330 attendees in 2017 is the sister meeting to both the popular American and Asian meetings held in San Diego and Singapore which bring together an even split of industry and academic delegates to discuss the latest microbiome science, the development of partnerships and commercial collaborations in this area and the growth of product pipelines.

An increasing awareness of the importance of the role different bacterial ecosystems play with regards to human and animal health has led to a surge in research, publications and companies coming out of the microbiome and probiotic space. As changes in our lifestyle and the growth of multi-drug resistant bacterial strains have also increased the need for better solutions and management of chronic and life-threatening illnesses, microbiome and probiotic research is one of the most scientifically important and potentially lucrative avenues to be exploring. There is mounting evidence that selected probiotic strains can confer health benefits to us especially in digestive diseases and paediatric health and the first microbiome-based drugs will be headed to market in the next few years.

Attracting over 375 attendees, the 14th meeting in the global series will build upon the success of last year’s meeting to explore the latest scientific research into the gut, skin, oral and lung microbiomes as well as commercial opportunities, pharma and biotech developments, regulation, intellectual property protection, food interactions and pro- and prebiotic research. This will be explored over the two days through a series of interactive presentations with leading academics and industry experts, panel discussions, roundtable discussions and an exhibition area allowing solution providers to showcase their products and services. The Global Engage series is rapidly gaining a fantastic reputation as the number one microbiome networking event for fostering partnerships across academia, pharma and biotech. If looking to either learn more from the top scientists in the microbiome and probiotic space; showcase exciting developments in your research; or seek partnerships and funding within the industry; it is a congress not to be missed!

JEREMY BURTONChair in Urological Sciences and is

the Deputy Director of the Canadian Centre for Human Microbiome and Probiotics, Lawson Health Research

Institute, Canada

CATHRYN NAGLERBunning Food Allergy Professor, University of Chicago, USA & Co-

Founder and President, ClostraBio

DIRK HALLERProfessor for Nutrition and

Immunology, Technical University of Munich, Germany

MICHELE TRUCKSISExecutive Vice President and Chief Medical Officer, Seres

Therapeutics, USA

EXPERT SPEAKERS Include:

5TH MICROBIOME R&D AND BUSINESS COLLABORATION FORUM / 2RD PROBIOTICS CONGRESS EUROPE 2018

EVENT SPONSORS


Platinum Sponsors

Other Sponsors & Exhibitors

Gold Sponsors

Silver Sponsors

CONFIRMED SPEAKERS

CATHRYN NAGLERBunning Food Allergy Professor, University of Chicago, USA & Co-Founder and President, ClostraBio

ANGELA HORVATHPost-Doctoral Researcher, Medical University of Graz, Austria

JOHN ZIBERTChief Medical Officer & Medical Director, Leo Innovation Lab, Denmark

SANDRINE CLAUSChief Scientific Officer, Laboratories Nutrition et Cardmetabolisme (LNC), France

CATH O’NEILLSenior Lecturer, University of Manchester, UK & CEO, SkinBio Therapeutics

JASON CHOUTeam leader for Microbiome and Metabolism, Nestlé Institute of Health Sciences, Switzerland

KIT WALLEN RUSSELLDirector of R&D, JooMo Ltd.

HENRIK BJØRN NIELSENCSO, Clinical Microbiomics

MICHELE TRUCKSISExecutive Vice President and Chief Medical Officer, Seres Therapeutics, USA

EGIJA ZAURAUniversity Research Chair Professor, VU University Amsterdam, the Netherlands

MYRIAM GOLEMBOVP Development, Biomx, Israel

ARANTXA LOPEZPostdoctoral Researcher, Alex Mira Lab, Center for Advanced Research in Public Health (CSISP), Spain

SENIOR REPRESENTATIVEJanssen Human Microbiome Institute

WEIYAN PENGBusiness Development Director of Novogene Europe

SHITAL TRIPATHIAssociate Director, Assembly Biosciences, USA

CÉLINE DRUARTAssistant Researcher, Louvain Drug Research Institute, Belgium

DIRK HALLERProfessor for Nutrition and Immunology, Technical University of Munich, Germany

JOHAN VAN HYLCKAMA VLIEGVice President Microbiome & Human Health Innovation, Chr. Hansen A/S

MORTEN ISAKSENCEO, Bio-Me

SARAH HEMMASIResearch Associate, Zymo Research Europe GmbH

TOM VAN DE WIELEAssociate Professor & CRIG Group Leader, University of Ghent, Belgium

ALEXANDRA ZHERNAKOVAAssociate Professor, University of Groningen, the Netherlands

TODD KRUEGERPresident, AOBiome

WOUTER DE JONGEProfessor of NeuroGastroenterology, AMC Amsterdam, the Netherlands

ALETTA KRANEVELDProfessor in Neuro-immunopharmacology, Utrecht University, the Netherlands

MONA BAJAJ-ELLIOTTSenior Lecturer, University College London, UK

PATRICE GARNIERCEO, Amabiotics, France

SENIOR REPRESENTATIVECosmosID

NAZIMA PATHANLecturer, University of Cambridge, UK

INA SCHUPPE-KOISTINENAlliance Director, Center for Translational Microbiome Research, Karolinska Institute

LUC STERKMANCEO, Caelus Health

MAGALI CORDAILLAT-SIMMONSScientific and Regulatory Affairs Director, Pharmabiotic Research Institute

BERNHARD PAETZOLDFounder, S-Biomedic

MAIREADH PEDERSENCEO, Quay Pharma

SENIOR REPRESENTATIVE4D pharma

NICK WALLENManaging Director & Co-Founder, JooMo Ltd.

BART SMITSenior Project Leader, Fermentation and Sustainability, NIZO Food Research

NILS HIJLKEMABusiness Development Manager, NIZO Food Research

MARTIN HORNSHAWDirector of Scientific Marketing, Metabolon

SENIOR REPRESENTATIVEDNA Genotek

KRISTIN NEUMANNSenior Coordinator at Lisando GmbH/Lysando AG

SENIOR REPRESENTATIVEVaiomer


MICROBIOME

JEREMY BURTONChair in Urological Sciences and is the Deputy Director of the Canadian Centre for Human Microbiome and Probiotics, Lawson Health Research Institute, Canada

ROSANNA PECEREExecutive Director, IPA Europe, Belgium

COLETTE SHORTTRegulatory Director Global Franchise Organisation- Emerging Science & Innovation, J&J Consumer, UK

HIMANSHU KUMARSenior Scientist, Danone Nutricia Research, the Netherlands

SARAH LEBEERAssociate Professor Microbiology & Biotechnology, University of Antwerp, Belgium

GASPAR PÉREZ MARTÍNEZHead of Laboratory of Lactic Acid Bacteria and Probiotics, IATA-CSIC, Spain

OLAF LARSENScience Manager, Yakult Nederland, Assistant Professor, VU University Amsterdam

CHARLÈNE ROUSSELPhD Student, University of Auvergne, France

KIRSI LAITINENDocent, University of Turku, Finland

THOMAS TOMPKINSResearch Director, Lallemand Health Solutions

SENIOR REPRESENTATIVEClinical Microbiomics

JUN SUNAssociate Professor, University of Illinois at Chicago

PASCAL RONFARDPresident, Group SOLACTIS SAS

NATHALIE CONNILAssociate Professor, University of Rouen, France

JISOO PAECEO, Genome & Company

CONFIRMED SPEAKERS PROBIOTICS

MICHELE TRUCKSISExecutive Vice President and Chief Medical Officer, Seres Therapeutics, USAMicrobiome Therapeutics: Rethinking Medical TherapyFecal microbiota transplants provide proof-of-concept that manipulation of the gut microbiome can provide therapeutic benefits in patients with ulcerative colitis. SER-287, an ecology of Firmicute bacterial spores, is postulated to decrease gut

inflammation by modifying the microbiome composition. A Phase 1b trial of SER-287 in adults with mild-to-moderate UC identified a dose-dependent effect in remission and endoscopic improvement. Study results will be discussed.

CONGRESS SCHEDULE DAY 1 WEDNESDAY 21ST MARCH 2018

08:50-09:30

KEYNOTE ADDRESS:CATHRYN NAGLERBunning Food Allergy Professor, University of Chicago, USA & Co-Founder and President, ClostraBioRegulation of Allergic Responses to Food by Commensal Bacteria

08:00-08:45

Global Engage Welcome Address and Morning Chair’s Opening Remarks:


Registration & Refreshments

08:45-08:50

09:30-09:55

09:30-09:55

ROSANNA PECEREExecutive Director, IPA Europe, BelgiumUnderstanding Probiotics in a European ContextEU rules on nutrition and health claims were established by Regulation (EC) No 1924/2006. Since their entry into force, all requests to put health claims on probiotics have been rejected by EFSA. Furthermore, there is no harmonized

approach within the EU regarding the presentation, labelling or advertising of probiotics in food. Consumers are therefore deprived of the information on the characteristics of the food, while at the same time research and innovation in this promising industry is severely stifled. This has led the industry and some member states to reflect on possible solutions and to reshape the future strategies of the probiotic food industry. In the presentation we will set out the legal options, explain the industry’s commitment for the use of the word “probiotics” and elaborate on the activity of IPA Europe to find the appropriate way to communicate on probiotics.

09:55-10:25

SPONSORED PRESENTATION:ANGELA HORVATHPost-Doctoral Researcher, Medical University of Graz, AustriaModulating the Microbiota-Gut-Liver Axis in Cirrhosis - Results from a randomized, controlled trialThe innate immune system of cirrhotic patients is challenged by an increased

level of gut derived bacterial products that enter the body through a leaky gut. In this setting, we tested the effects of a six months intervention with Ecologic® Barrier (Winclove, Amsterdam, The Netherlands) on microbiome composition, bacterial translocation and innate immune function in a randomized, double blind, placebo-controlled study. Probiotics could enrich the intestinal microbiome with Lactobacillus brevis and Lactococcus lactis, suppress the abundance of Enterococcus faecium, and increase neutrophil resting burst and serum neopterin levels. Furthermore, health related quality of life could be improved for the duration of the intervention. In conclusion, probiotic supplementation had beneficial effects on the intestinal microbiome, innate immunity and the general well-being of patients.

09:55-10:25For sponsorship opportunities contact Gavin Hambrook at

Email: [email protected] Tel: +44 (0) 1865 849841

SOLUTION PROVIDER PRESENTATION

MICROBIOME PROBIOTICS

Odd Numbered Poster Presentations - Grab a refreshment and head over to view a wide selection of posters. A full poster abstract book can be viewed online prior to the congress and a summary of posters is viewable at the bottom of the agenda10:25-11:35Morning Refreshments / Scheduled One-to-One Meetings

CONGRESS SCHEDULE


11:35-12:00

11:35-12:00

JOHN ZIBERTChief Medical Officer & Medical Director, Leo Innovation Lab, DenmarkEffects of Dietary Changes in Psoriasis Patients based on their Microbiome Profiling

11:35-12:00

SHITAL TRIPATHIAssociate Director, Assembly Biosciences, USARealizing the Promise of the Microbiome: Using Rigorous Principles of Drug Development and a High-throughput Research Platform

• Summary of our differentiating features and strategy of our Live Bio-therapeutic Product (LBP) development

• Exemplar data from our research and development projects aimed at developing various LBPs

MICROBIOME DRUG DEVELOPMENT SKIN MICROBIOME PROBIOTICS CONGRESS

DAY 1 WEDNESDAY 21ST MARCH 2018

12:00-12:25

12:00-12:25

CATH O’NEILLSenior Lecturer, University of Manchester, UK & CEO, SkinBio TherapeuticsThe Gut-Skin Axis in Health and DiseaseAs crucial interface organs, gut and skin have much in common. Therefore, it is perhaps

unsurprising that conditions affecting one organ also have manifestations in the other. Nevertheless, the reasons underlying this are largely unexplored and neither Dermatology nor Gastroenterology has systematically investigated the possibility of a 'gut skin axis'. In this talk, I will review the possible mechanistic levels on which gut and skin may interact. Principally, I will focus on the microbiota, which, with its huge metabolic capacity may be a principle player along the gut skin axis. I will also suggest that intervention in the gut microbiota, using probiotics, may offer new therapeutic strategies for skin in health and disease.

12:00-12:25HIMANSHU KUMARSenior Scientist, Danone Nutricia Research, the NetherlandsBifidobacteria as a marker for healthy life

SANDRINE CLAUSCSO, Laboratories Nutrition et Cardmetabolisme (LNC), FranceMicrobiome-Directed Therapeutics to tackle metabolic disorders• Why Microbiome-Directed Therapeutics

(MDT) are interesting therapeutic agents to address metabolic disorders associated with gut microbial dysbiosis

• The promise and limitations of MDT

NATHALIE CONNILAssociate Professor, University of Rouen, FranceThe Genus Enterococcus as ProbioticEnterococci belong to the group of lactic acid bacteria (LAB), and are normal inhabitants of the gastrointestinal tract of humans and

animals. These bacteria have many favourable characteristics for the production of cheese, and are present in other fermented foods such as sausages, olives and vegetables. Furthermore, a large number of Enteroccocus strains has been studied for food preservation, as they produce bacteriocins (enterocins), antimicrobial peptides with the potential to inhibit the growth of food-borne pathogenic and spoilage bacteria. Some of these bacteria have been proposed to be used as probiotics to promote health. However, the genus Enterococcus contains also important nosocomial pathogens that cause bacteraemia, endocarditis and other infections. Some strains of E. faecalis and E. faecium are resistant to many antibiotics and possess virulence factors. Thus, the role of enterococci in disease has raised questions on their safety for use in foods or as probiotics.

CONGRESS SCHEDULE



12:50-13:20

SPONSORED PRESENTATION:HENRIK BJØRN NIELSENCSO, Clinical MicrobiomicsMetagenomics Platform for Microbiome Discovery and Clinical ResearchClinical-Microbiomics is a world leading

contract research organization specialized in microbiome metagenomics. Through state-of-the-art sequencing and development of tailor-made bioinformatics tools, we assist partners across pharmaceutical, food, nutritional and agricultural industries to extract key biological insights from microbiome research. Our proprietary bioinformatics toolbox and continuous innovation pipeline provides our partners with unmatched capabilities to analyze and interpret microbiome metagenomics, including proven track-record of integration of big data, such as metabolomics, metatranscriptomics and clinical data. With a unique partnering approach, our microbiome experts guide and optimize your study from experimental design to final analysis and interpretation. We are committed to sharing our knowledge and expertise and will thoroughly review all findings with you to provide actionable microbiome insights to accelerate your research.

12:50-13:20

For sponsorship opportunities contact Gavin Hambrook at Email: [email protected]

Tel: +44 (0) 1865 849841


12:50-13:20

12:25-12:50

12:25-12:50

NICK WALLENManaging Director & Co-Founder, JooMo Ltd

KIT WALLEN RUSSELLDirector of R&D, JooMo Ltd.Skin Microbiome and CosmeticsThere is a skin allergy epidemic raging across the western world, which has been suggested by some to be linked to the rise in use of synthetic chemicals in modern cosmetics. JooMo Co-Founder, Kit Wallen Russell reveals his new groundbreaking peer-reviewed and published

research, and gives details of the discovery of an extraordinary link between the biodiversity of the skin and its health, and the subsequent development of the first mechanism to test for skin health. Using this mechanism for the first time, clinical trials to test whether it is modern cosmetics damaging the skin’s microbiome in the western world are already underway. ‘Third Wave’ cosmetics are proposed as the solution to the skin allergy epidemic, heralding a new era of health-conscious, research driven companies selling honestly labeled products, which are 100% truly natural.

12:25-12:50

SARAH LEBEERAssociate Professor Microbiology & Biotechnology, University of Antwerp, BelgiumExploring probiotics for the upper respiratory tract: from microbiome profiling towards screening and formulation of isolates

In our ungoing ProCure project (www.procureproject.be), we profile the microbiome of the nose, nasopharynx, sinuses and other respiratory niches of healthy volunteers and patients with chronic disorders. We also isolates potential probiotic strains from genera and species that are more prevalent in health than in disease. These isolates are characterized for potential probiotic activities and various formulations and dosage forms are explored.

JASON CHOUTeam leader for Microbiome and Metabolism, Nestlé Institute of Health Sciences, SwitzerlandTitle TBC

SPONSORED PRESENTATION:BART SMITSenior Project Leader, Fermentation and Sustainability, NIZO Food ResearchProcess Development and Production of Strict Anaerobes and Probiotics from Gut and Skin

At this moment new probiotic species applied in diverse niches (Gut, Skin, Oral cavity) are under fast development. One may not only think of strains belonging to the Bifidobacteria, but also Eubacteria, Akkermansia, Propionibacteria, Clostridiaceae, Blautiaceae, Faecalibacteria, etc. Growing, processing and formulation of these bacteria on production scale is very species and strain dependent and pose a range of challenges. Therefore optimization of the economics of the probiotics plays in an ever more important role in the commercialization process. NIZO’s Probiotics Optimisation Pipeline supports from microbial discovery to health claim support. During the presentation we will elaborate on the actual challenges in safety assessments, optimization of production parameters in fermentation and downstream processing steps and in formulating and stabilizing strains. The NIZO way of working is to test feasibility of the process at lab scale before entering into larger scale productions within the food grade facilities at NIZO. In the presentation we will showcase examples of our pipeline.

CONGRESS SCHEDULE


MICROBIOME DRUG DEVELOPMENT SKIN MICROBIOME PROBIOTICS CONGRESS

14:45-15:10

14:45-15:10

14:45-15:10

OLAF LARSENScience Manager, Yakult Nederland, Assistant Professor, VU University AmsterdamLinking gut health and microbiota diversityMany scientific reports link a decreased diversity of the gut microbiota to a declined

health status. However, to date, no mechanistic motivation for this exists. In this presentation it is shown that by applying first principles graph theory to small and simple networks, an increased diversity indeed leads to both higher efficiency as well as redundancy [1]. The simulation results quantitatively support earlier hypothetical considerations with respect to the aforementioned parameters, illustrating that a higher diversity in small microbial networks leads to more resilience. This provides an ingredient for the development of new new interventional strategies with respect to microbiota management.

[1] Larsen, O.F.A., & Claassen, E. (2018). The mechanistic link between health and gut microbiota diversity. Nature Scientific Reports, In press.

MYRIAM GOLEMBOVP Development, Biomx, Israel BiomX – Novel Therapeutics through Microbiome ModulationSince 2015, BiomX has been developing innovative microbiome-based therapeutics to

prevent and treat cancer, IBD, and skin disorders that stem from microbiome dysbiosis. The Company’s microbiome modulation platform uses cutting-edge science and licensed technology created by its founders, Professor Rotem Sorek, Ph.D., and Prof. Eran Elinav, M.D./Ph.D., both of The Weizmann Institute; and Professor Timothy K. Lu, M.D./Ph.D., of The MIT. BiomX most advanced product candidates include BX001 for acne and BX002 for IBD both at preclinical development stages. BX002 is a phage cocktail eradicating several proprietary bacteria targets associated with the onset of IBD and provides a unique therapeutic approach to the disease. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset Global Investments, private Swiss investors and SBI.


EGIJA ZAURAUniversity Research Chair Professor, VU University Amsterdam, the NetherlandsThe Host and its Oral MicrobiomeThe human microbiome has evolved in symbiosis with its host for thousands of years.

This has resulted in highly efficient host-bacterial mutualism. Hundreds of bacterial taxa and other microorganisms interact with each other and with their environment, which is provided by the host. It is known that genetic and behavioural factors of the host are shaping the microbiome. In this talk the current knowledge on the role of the host factors such as salivary properties, gender, dietary and behavioural habits of the host, as well as general health of the host on the oral microbiome and oral health will be discussed.

ALEXANDRA ZHERNAKOVAAssociate Professor, University of Groningen, the NetherlandsThe Microbiome: Interaction of Genes, Food, and EnvironmentMultiple studies have examined the role of

the gut microbiome in immune and metabolic processes and in diseases, yet little is known about which factors shape the microbiome composition in healthy individuals. We recently analyzed hundreds of dietary, intrinsic, medication and lifestyle factors in healthy Dutch population and their effect on the gut microbiome. By performing the metagenomics sequencing in >1000 samples, we could zoom in to bacterial species and pathways. In this presentation I will discuss the effect of environmental, food and genetic factors on the development and composition of the gut microbiome. I will highlight the most important environmental factors that shape the gut ecosystem. I will further discuss the role of the microbiome in gastrointestinal diseases (Inflammatory Bowel Disease and Irritable Bowel Syndrome), and the link between the host genetics and gut microbiome.

14:20-14:45

14:20-14:45

14:20-14:45

GASPAR PÉREZ MARTÍNEZHead of Laboratory of Lactic Acid Bacteria and Probiotics, IATA-CSIC, SpainBiotechnological Development of Peptide Domains from Probiotic Bacteria that Stimulate Intestinal Epithelial Proliferation and Repair

Two secreted multifunction proteins of the probiotic strains L.casei BL23 and L.rhamnosus GG (p40 and p75) have been reported to have antiapoptotic and IgA stimulating features. They are autolysins containing an active C-terminal domain of the NLPC/P60 family. Their genes have been cloned, deleted and the proteins purified to determine the smallest fragment retaining biological activity and affinity for cell surface components. New intriguing properties of these proteins have been revealed through the study of the internalization of whole bacterial cells into intestinal epithelial cells. Finally, surface Plasmon Resonance affinity assays and intestinal epithelial cell responses suggested that both proteins may have different receptors or mediators and that the N-terminus region is involved in the biological activity of these proteins.

BERNHARD PAETZOLDFounder, S-BiomedicDirect modulation of the skin microbiome as new therapeutic approach to Acne vulgarisThe influence of Cutibacterium acnes (former Propionibacterium acnes) in the pathogenesis

of acne has been long known. New insights into composition of the skin microbiome from humans enable the modulation of the P. acnes population as a new therapeutic option for various dermatoses. We carried out a prospective study of 18 healthy subjects in which our microbiota preparations were investigated in different sebaceous gland rich regions regarding galenics and safety aspects. No local skin irritations or other intolerances were observed over a period of 16 weeks after 3 days of application. In a clinical follow-up study we tested direct microbiome modulation in 14 mild acne cases and will present first results from this study.

13:20-14:20

Lunch

SPONSORED BY:

CONGRESS SCHEDULE


15:35-16:05

SPONSORED PRESENTATION:WEIYAN PENGBusiness Development Director of Novogene EuropeAdvanced Technical Solutions for Microbiome

As a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, Novogene invests over €10 Million for R&D every year. Here Novogene will present the latest next-generation sequencing applications especially for microbiome research, including state-of-the-art sequencing technologies and bioinformatics solutions.

15:35-16:05

For sponsorship opportunities contact Gavin Hambrook atEmail: [email protected]

Tel: +44 (0) 1865 849841


15:35-16:05


Tel: +44 (0) 1865 849841


Afternoon Refreshments / One-to-One Meetings16:05-16:55


ARANTXA LOPEZPostdoctoral Researcher, Alex Mira Lab, Center for Advanced Research in Public Health (CSISP), SpainHealth-Associated Niche Inhabitants as Oral Probiotics

Oral diseases, including dental caries and periodontitis, are among the most prevalent diseases worldwide and develop as a consequence of a microbial dysbiosis. Several bacterial strains are being tested as potential oral health-promoting organisms, but usually they are species isolated from niches other than the site where they must exert its probiotic action. We hypothesize that oral inhabitants associated to health conditions will be more effective than traditional, gut-associated probiotic species in key aspects such as colonization of the oral site where disease takes place or the possession of oral health promoting functions. As an example of these active colonizers, we describe the case of Streptococcus dentisani, a new streptococcal species isolated from dental plaque of caries-free individuals with a double probiotic action, as it inhibits the growth of major oral pathogens through the production of bacteriocins, and also buffers acidic pH (the primary cause of dental caries) through an arginolytic pathway.

14:45-15:10

14:45-15:10

14:45-15:10

CHARLÈNE ROUSSELPhD Student, University of Auvergne, FranceMarry TIM & SHIME for an in-depth understanding of the anti-infectious properties of probiotic Saccharomyces cerevisiae against ETEC food-borne pathogens in the human gut

• ETEC are major food and waterborne pathogens, responsible for hundreds of millions of diarrheal episodes worldwide including traveler’s diarrhea and infant diarrhea.

• Treatments of ETEC infections remain only symptomatic. Given the rise of antibioresistance worldwide, there is a crucial need to develop alternative prophylactic strategies, such as the use of probiotics.

• Studies involving pathogens are obviously prohibited in humans and animal experiments may be hampered by differences between animal and human digestive physiology. In vitro digestion methods emerge as an appropriate alternative to in vivo assays provided that we can ensure that physiologically relevant conditions are reproduced.

• For the first time, the collaboration between UMR MEDIS and cmet allows to gather the TIM (TNO gastrointestinal model) and SHIME (Simulator of the Human Intestinal Microbial Ecosystem) which are the most complete simulators of the upper and lower GIT, respectively.

• These two complementary in vitro models have been used to deeply investigate how the probiotic yeast Saccharomyces cerevisiae CNCM I-3856 can modulate ETEC survival and virulence all along the human GIT and interact with gut microbiota.

SENIOR REPRESENTATIVE (Reserved)Janssen Human Microbiome InstituteBugs as Drugs

CONGRESS SCHEDULE


Complimentary Drinks Reception / End of Day 118:00-19:00

17:10-17:35

17:10-18:00

ROUNDTABLE DISCUSSIONS:Table 1: Securing FundingCATH O’NEILLSenior Lecturer, University of Manchester, UK & CEO, SkinBio Therapeutics

Table 2: IP Protection• Categories of microbiome therapeutics• Strategies for patenting• Challenges in the regulatory landscape

Table 3: Industry-Academic CollaborationsINA SCHUPPE-KOISTINENAlliance Director, Center for Translational Microbiome Research, Karolinska Institute• Structuring successful collaborations• Case study examples• Spin-outs

Table 4: Microbiome Development from Laboratory to Clinical LeadLUC STERKMANCEO, Caelus Health• Fecal microbiota transplant studies• Selection of donors• Identification of microbiome leads for further development• Lead evaluation – key aspects to consider• Lead optimisation – mutagenesis and/or CRISPR/CAS• Formulation development

17:35-18:00

CÉLINE DRUARTAssistant Researcher, Louvain Drug Research Institute, BelgiumTranslational development of Akkermansia to target metabolic disorders: from mice to humanWho is Akkermansia muciniphila? Brief overview of a bacterium considered as a next generation beneficial microbes and summary of more than 10 years of

investigation from mice to man: • 2004: discovery of Akkermansia muciniphila by Willem de Vos team. • 2007: food impact on the abundance of Akkermansia, role of fat versus fibers• 2013: demonstration that Akkermansia reduces diet-induced obesity, fat mass development,

diabetes and gut barrier dysfunction in mice• 2015: first administration of Akkermansia in humans : the Microbes4U study starts in Belgium• 2017: pasteurized Akkermansia and the newly discovered protein Amuc_1100 isolated

from Akkermansia abolished diet-induced weight gain fat mass, liver fat and inflammation, hypercholesterolemia and normalized gut barrier.

• 2017: proof of the safety of live and pasteurized A. muciniphila administration in human• 2018: Wat’s next?



16:55-17:10

COMPANY SHOWCASE:NILS HIJLKEMABusiness Development Manager, NIZO Food ResearchThe NIZO Approach for Creating Data Driven, Expert Based Modulation Technologies for Microbiome Niches in Health and DiseaseNIZO is world leading in contract research for better food and health. We

believe food and health are becoming increasingly connected. That’s why we are convinced that working closely with our customers, both corporate and start-up companies in food and health, is the only road to success. NIZO specializes in helping companies in obtaining insights in the microbiome as well as developing technologies for microbiome modulation in niches such as gut, skin and women’s health. We deploy both our biological expertise and a unique set of data generation and interpretation tools to realize this. These microbiomics tools consist of:• in silico predictive tools such as NIZO Connect/Predict• in vitro microbiome screening models such as MicroColon and MicroSkin• Clinical (challenge) studies• NIZO Pre/probiotic Optimisation Pipeline (POP)• Stabilization and production of live bacteria/probiotics including strict anaerobesThis presentation showcases our iterative way of working and explains why NIZO is the hotspot for microbiome research.

16:55-17:10

COMPANY SHOWCASE:JISOO PAECEO, Genome & CompanyWe have been studying microbes and probiotics which can be applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies with the vision of becoming the Asian Flagship Company of the Human Microbiome

Industry and the objective of market driven product development by 2018. We seek to identify what causes diseases, integrating the functional mechanism using a simulator of the human colon microbial ecosystem and multi-omics profiling through Next generation sequencing.

Invitation Out

CONGRESS SCHEDULE

08:45-09:25

KEYNOTE ADDRESS:DIRK HALLERProfessor for Nutrition and Immunology, Technical University of Munich, GermanyFunctional Relevance of Microbiome Signatures – Inflammation Meets Colon Cancer• Transfer studies of human microbiota in germfree mouse models

• Transfer studies of dysbiotic microbiota in IBD and cancer models• Identification of pathobionts relevant for IBD and colon cancer• Identification of host target mechanisms in inflammation and colon cancer

08:00-08:40


08:45-09:25

Refreshments


DAY 2 THURSDAY 22ND MARCH 2018

09:25-09:50

JOHAN VAN HYLCKAMA VLIEGVice President Microbiome & Human Health Innovation, Chr. Hansen A/SMicrobes Matter - More than Ever• Mining culture collections for next generation probiotics and live biotherapeutics• Lactic acid bacteria and Bifidobacteria remain highly relevant in the Microbiome Era• Future outlook 09:25-09:50

KIRSI LAITINENDocent, University of Turku, FinlandInteractions among Diet, Microbiota and Metabolism in Advancing the Health of Overweight Pregnant WomenOverweight during pregnancy predisposes both the mother and foetus to health complications. Maternal complications include an increased risk of gestational

diabetes and type 2 diabetes in years to come. Both diet and human gut microbiota are known to contribute to the health by regulating the host metabolism. Although the adult gut microbiota is generally considered consolidated, external factors, such as diseases and diet, may modify the composition and activity of the gut ecosystem. It is also possible that some metabolic effects of diet are mediated through gut microbiota. In other words, diet and gut microbiota both have direct effects on metabolism and human health, but gut microbiota may also act as a metabolic link between the diet and the host health. The diet-microbiota-metabolism relationships during pregnancy are mostly unknown but may underlie the clinical health outcomes. We have explored these relations in a randomized mother-child intervention trial involving probiotics and long-chain polyunsaturated fatty acids.

KEYNOTE ADDRESS:JEREMY BURTONChair in Urological Sciences and is the Deputy Director of the Canadian Centre for Human Microbiome and Probiotics, Lawson Health Research Institute, CanadaThe Role of the Microbiome in Urological Health and TreatmentThe urinary tract was long assumed as sterile in healthy individuals. However, it

is now known to harbour a microbiome, and as with any exposed epithelial tissue, the microbiome present is assumed to play a role in maintaining health at this site. The microbiome associated with the urinary system is challenging to index because of its low abundance; there is difficulty when attempting to directly sample above the urethra due to microbial contamination. Studies of the urinary microbiota have identified differences between healthy populations and those with certain conditions, including a potential role in urologic cancers and kidney stones. While the gut microbiome is distant from the urinary system, it may also have a profound effect on urologic health due to its metabolic output and the xenobiotic metabolism of orally ingested urological-targeted medications. New insights into the urinary and intestinal microbiomes of people with urological conditions might provide an opportunity to predict the risk of developing certain diseases and could enable the development of innovative microbiome-based therapeutic strategies.

CONGRESS SCHEDULE


Even Numbered Poster Presentations - Grab a refreshment and head over to view a wide selection of posters. A full poster abstract book can be viewed online prior to the congress and a summary of posters is viewable at the bottom of the agenda10:25-11:35Morning Refreshments / Scheduled One-to-One Meetings


GUT MICROBIOME OUTSIDE THE GUT PROBIOTICS CONGRESS

09:55-10:25

SPONSORED PRESENTATION:THOMAS TOMPKINSResearch Director, Lallemand Health SolutionsA systematic review with meta-analysis of a Pharmabiotic composition for

the management of Ulcerative Colitis remission in a Chinese populationMedilac-S is a pharmabiotic sold by Hanmi Pharmaceuticals in Asia, primarily China and Korea, where it is registered as a pharmaceutical. This product has been used in a number of applications such as the management of symptoms of irritable bowel syndrome, acute gastritis and liver cirrhosis as well as improving the outcome associated with Helicobacter pylori therapy. The main clinical documentation of this product has been the efficacy in the induction and/or maintenance of remission in patients with Ulcerative Colitis when co-administered with conventional drug therapy, mesalazine, sulfasalazine or olsalazine. A search of Chinese and English databases identified over 80 clinical papers for this application. Systematic review with meta-analysis was registered in PROSPERO and run according to PRISMA protocols. Meta-analysis was completed using the metafor package in R. Most of the studies scored patients according to standard Chinese guidance documents for UC and changes were reported as markedly effective, effective or ineffective. Other studies used the Sutherland Index, symptomology, histopathology and/or colonoscopic evaluation. A daily dose of 2 capsules t.i.d. corresponding to 3.0 x 10e9 CFU/day was commonly used and the duration intervention was generally between 4 and 12 weeks. In maintenance studies recurrence rate was evaluated after a 6 month follow up. Results of the meta-analysis will be presented as risk of bias assessment, induction of remission, maintenance of remission and stratified by concurrent drug therapy

09:55-10:25

09:55-10:25

SPONSORED PRESENTATION:MAIREADH PEDERSENCEO, Quay PharmaOral Delivery of Live Bio-Therapeutics: Drug Product Development for FIM Studies• Key CMC considerations for the

development of an LBP product.• Critical factors affecting time-lines when outsourcing

GMP manufacturing activities of LBP drug products• Incorporating Quality (systems and regulations) into early

phase dosage form design of LBP drug products

SPONSORED PRESENTATION:MARTIN HORNSHAWDirector of Scientific Marketing, MetabolonMetabolomics Provides a Powerful Approach to Understanding how the Microbiome Affects Health & Disease Progression

Studies highlighting key contributions of our commensal microbiota to health and disease continue to mount and while many recent publications associate different bacteria to certain diseases, they have sometimes been criticized for failing to clarify how the microbiome functionally influences disease or promotes health. The language and currency of microbial communities throughout nature are small molecules – metabolites. The systematic application of metabolomics to microbiome research is remarkably feasible and combining metabolomics with traditional microbiome genetic research tools has resulted in some exciting findings, particularly in gut microbiome research. Recent examples of how metabolomics has informed analyses of the functional consequences of a changing microbiome in health and disease will be discussed.

CONGRESS SCHEDULE



11:50-12:15

11:50-12:15

11:50-12:15

TOM VAN DE WIELEAssociate Professor & CRIG Group Leader, University of Ghent, BelgiumAdvanced gut simulation technology to chase personalized health effects from novel health ingredients

JUN SUNAssociate Professor, University of Illinois at ChicagoProbiotics modulate the vitamin receptor-autophagy signaling pathwaysVitamin D receptor (VDR) plays an essential

role in pathogenesis of various human diseases, including inflammatory bowel disease (IBD). Our recent study (Wang, et al, Nature Genetics, 2016) has demonstrated that human VDR is a key host factor to shape gut microbiome. Further, our study has demonstrated that intestinal epithelial VDR conditional knockout (VDRΔIEC) leads to dysbiosis. Low expressions of VDR is associated with impaired autophagy, accompanied by a reduction of ATG16L1 and LC3B (Wu, et al, Gut, 2015). Here, we highlight the beneficial effects of probiotic Lactobacillus strains, isolated from Korean Kimchi, in upregulating VDR signaling and autophagic responses and suppressing inflammation. Our data indicate novel therapeutic and beneficial roles of probiotics in inhibiting inflammation and infection.

Invitation Out

11:35-11:50

COMPANY SHOWCASE:MORTEN ISAKSEN CEO, Bio-MeA Microbiome-based approach to Precision Medicine and Personalized Nutrition

Precision Medicine and Personalized Nutrition has been hailed as the new wave in Health treatment and prevention. Bio-Me develops a high resolution, accurate, high throughput and low cost analysis method for gut microbiome analysis. In addition, Bio-Me has entered into a unique collaboration agreement with a Norwegian university (NTNU) that gives Bio-Me access to analyze approximately 30.000 fecal samples from an ongoing population based health study, together with access to hundreds of different genetic, life-style and other health parameters for each sample donor. This will make it possible for the first time to obtain detailed information at species and strain level from the gut microbiome of a large number of participants, and correlate this information to various health conditions in a controlled environment. The talk will highlight some initial data from the development of this test, and point out possible useful applications within Precision Medicine and Personalized Nutrition

11:35-11:50

COMPANY SHOWCASE:SENIOR REPRESENTATIVE Clinical MicrobiomicsClinical-Microbiomics is a world leading contract research organization specialized in microbiome metagenomics.

Through state-of-the-art sequencing and development of tailor-made bioinformatics tools, we assist partners across pharmaceutical, food, nutritional and agricultural industries to extract key biological insights from microbiome research. Our proprietary bioinformatics toolbox and continuous innovation pipeline provides our partners with unmatched capabilities to analyze and interpret microbiome metagenomics, including proven track-record of integration of big data, such as metabolomics, metatranscriptomics and clinical data. With a unique partnering approach, our microbiome experts guide and optimize your study from experimental design to final analysis and interpretation. We are committed to sharing our knowledge and expertise and will thoroughly review all findings with you to provide actionable microbiome insights to accelerate your research.

11:35-11:50

COMPANY SHOWCASE:SARAH HEMMASI Research Associate, Zymo Research Europe GmbH ZymoBIOMICS - The Complete Microbiomics Solution. Improving

the Accuracy and Reproducibility of Microbiome Measurements Across LabsZymo Research has the goal to provide researchers the best tools for microbiome measurement to ensure standardized microbiomic workflows. The ZymoBIOMICS™ portfolio has been developed to eliminate bias across microbiomics workflows and offers a complete pipeline from start-to-finish for all your microbiome related needs. ZymoBIOMICS™ offers a complete workflow, from sample collection to analysis, which offers streamlined collection, purification, and the first microbial community standards.

CONGRESS SCHEDULE



14:05-14:20


Tel: +44 (0) 1865 849841


14:05-14:2011:50-12:15

ROUNDTABLE DISCUSSIONS:Table 1: Making Sense of Microbiome Data• Tools to analyse microbiome data• Generating data from the public• How do we make meaningful use of data

Table 2: Microbiome and Cancer Immunotherapy• Understanding the microbiome in immunotherapy• Innovation in immunotherapy-microbiome research• Using the microbiome to predict response• Future Directions

Table 3: Gut-Brain Connections

Table 4: Regulatory aspects for LBPsMAGALI CORDAILLAT-SIMMONSScientific and Regulatory Affairs Director, Pharmabiotic Research Institute

12:15-12:40

PASCAL RONFARDPresident, Group SOLACTIS SASUnlocking the power of digestive health and intestinal microbiota through innovation in prebiotics

12:40-13:05

GABRIELE GROSS (Reserved)Principal Scientist / Project Leader, Global Discovery R&D, Mead Johnson Nutrition, the NetherlandsPrebiotics – Title TBC

13:05-14:05

Lunch

SPONSORED BY:

12:40-13:05

PANEL DISCUSSION: Growing a Microbiome Business• Examining the challenges of growing a microbiome business• Growing microbiome focus and expertise within established

companies• Structuring collaborations

TODD KRUEGERPresident, AOBiome

INDUSTRY REPRESENTATIVES X2

12:15-12:40

SPONSORED PRESENTATION:SENIOR REPRESENTATIVE4D PharmaTitle TBC

14:05-14:20

SPONSORED PRESENTATION:SENIOR REPRESENTATIVEDNA GenotekTitle TBC

SPONSORED PRESENTATION:SENIOR REPRESENTATIVEVaiomerTitle TBC

SPONSORED PRESENTATION:KRISTIN NEUMANNSenior Coordinator at Lisando GmbH/Lysando AGTargeted microbiome modification with Artilysin®

Restoring the microbiome is a big task. Methods used are probiotics, prebiotics, fecal transplants, a versatile nutrition and so on… in most cases we are facing the problem that the bacteria which already occupy our body space will not move when the new ´good´ bacteria are knocking on the door. They created their comfort zone, making it hard for the new tenants to move in. In this way, many probiotic treatments cannot be efficient! Imagine you can specifically remove the unwelcomed tenants before the new, beneficial tenants move in! We are presenting the solution! Artilysin®s are artificially designed antibacterial proteins, which can specifically kill undesired bacteria without affecting the beneficial commensal bacteria. Artilysin®s work fast, selective and without side effects.

CONGRESS SCHEDULE



14:35-15:00

14:35-15:00

14:35-15:00WOUTER DE JONGEProfessor of NeuroGastroenterology, AMC Amsterdam, the NetherlandsThe Microbiota Directing Functional and Inflammatory Bowel Disease-Future Challenges• The state of the art in the functional role of

microbiota dysbiosis in IBS and IBD, our learnings from FMT studies and preclinical work

• Metabolic activity of microbiota relating to epithelial barrier function and mucosal tolerance

• Molecular pathways explaining how luminal metabolites can fortify mucosal tolerance in early life, and the relevance of those findings for design of optimal neonatal nutrition

COLETTE SHORTTRegulatory Director Global Franchise Organisation- Emerging Science & Innovation, J&J Consumer, UKEuropean Food Regulatory Landscape for Pre/Probiotics: Quo Vadis?

Invitation Out

14:20-14:35

SPONSORED PRESENTATION:SENIOR REPRESENTATIVECosmosIDTitle TBC

14:20-14:35

14:20-14:35


Tel: +44 (0) 1865 849841


CONGRESS SCHEDULE


15:00-15:25

15:00-15:25

MONA BAJAJ-ELLIOTTSenior Lecturer, University College London, UKCauses and Consequences of Clostridium difficile Colonisation in Hospitalised ChildrenClostridium difficile is the leading cause of antibiotic-associated diarrhoea worldwide. In adults (>65 years of age), C. difficile infection and associated

diseases (CDI/CDAD) represent a significant burden of morbidity and mortality. The depletion of normal healthy microbiota in conjunction with bacterial toxin-secretion invariably promotes gastrointestinal (GI) pathology in CDAD. Although details remain unclear, disease remission seen in response to faecal transplantation, confirms the importance of the microbiome in curbing the assault by this enteropathogen. Neonates and children under the age of two can be heavily colonised with C. difficile, with the rates of colonisation declining to adult levels above 2 years of age. The impact of C. difficile colonisation on GI homeostasis in the paediatric population has not been studied, although recent studies do implicate increased risk of food allergy in C. difficile carriers. I will present our early findings on the potential effect of C. difficile on the paediatric GI tract.

ALETTA KRANEVELDProfessor in Neuro-immunopharmacology, Utrecht University, the NetherlandsThe microbiome-brain axis in Parkinson’s Disease: no guts no gloryThe frequently reported intestinal discomfort, constipation, leaky gut, intestinal inflammation and changes in the composition of the microbiome in patients point to the involvement of microbiome-gut-brain axis in Parkinson’s disease. The

relevance of microbiome-gut-brain axis in Parkinson’s disease will be presented from preclinical and clinical perspectives. Both human and animal studies suggest that toll-like receptor 4 (TLR4)-mediated gut-induced neuroinflammation could play an important role in intestinal as well as central neurodegenerative processes in Parkinson’s disease. In addition, a diet containing nutritional precursors and cofactors required for membrane phospholipid synthesis, as well as prebiotic fibres, has therapeutic effects in a mouse model for PD. Moreover, the dietary intervention might confer clinical benefits on levodopa treatment. A poor gut function leads to a poor brain function; therefore, targeting the intestinal microbiome and the neuro-immune system with medical food interventions and/or pharmaceutical compounds could be a new approach for the therapy of CNS disorders


GUT MICROBIOME OUTSIDE THE GUT

15:25-15:50

PATRICE GARNIERProfessor in Neuro-immunopharmacology, Utrecht University, the NetherlandsTranslating Microbiome Science into Effective Innovative Therapies • Microbiome-based Therapies: a large set of strategies!• A successful example: AMA-101, a potential first-in-class therapy for Parkinson’s disease.• Microbiome Indication-screening process: a new paradigm for drug discovery• Microbiome-derived Diagnostics: a way for personalized medicine?

NAZIMA PATHANLecturer, University of Cambridge, UKThe Gut Microbiome in Critical Illness - Dysbiosis and Metabolic DysfunctionCritical illness is associated with significant morbidity and is a costly healthcare burden. The intestinal microbiome makes many contributions to host physiology including fermentation, immune, metabolic and endocrine activities. Dysbiosis of the microbiome in

critical illness is likely due to iatrogenic factors as well as disease pathophysiology. The microbiome of critically ill individuals suffers profound depletion of species associated with intestinal health, and relative collapse of the trophic fermentation network. The faecal microbiome in critical illness is characterised by loss of fermentative commensals and producers of host-beneficial co-metabolites. This correlates with marked reduction in measured levels of beneficial bacterial co-metabolites, alongside increased abundance of metabolic intermediates. This is likely to impact on wider organ dysfunction including severity of lung injury and cardiovascular compromise.

Afternoon Refreshments / Conference Close15:50-16:20

15:00-15:25

POSTER PRESENTATIONS

MAKING A POSTER PRESENTATION

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). We charge an admin fee of £100 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee is waived for those representing academic institutions and not for profit organisations.

VENUE INFORMATION

Postillion Convention Centre WTC Rotterdam,Beursplein 37,3011 AA Rotterdam,The Netherlands

In the vibrant heart of the Rotterdam metropolis: you cannot get more central than this. Wherever you are in the world, a World Trade Center is a special place. It is an (inter)national corporate community, in a unique building that meets the highest standards. From high-spec office space to high-tech meeting rooms, shops, restaurants and a wide range of additional services.

• A non-stop high-speed train runs between Rotterdam and Schiphol (Amsterdam airport) every 20 minutes. The journey time is 20 minutes. Cost €22 Euros

• Located in the city centre (surrounded by shops, architecture, museums, restaurants and the Port of Rotterdam)

• Walking distance from the international train station• Rotterdam – The Hague airport with flights to at least 30

international destinations is a short taxi ride• A large number of parking facilities can be found in the area • A wide variety of hotels are within walking distance. (Details will be

sent to you in your welcome letter when you register)


5 microbiome r&d business collaborationforum … · science manager, yakult nederland,...

Documents